Affiliation: University of California
- Hypothesis testing of a change point during cognitive decline among Alzheimer's disease patientsMing Ji
Division of Epidemiology and Bisotatistics, Graduate School of Public Health, San Diego State University, 5500 Campanile Drive, San Diego, CA 92182 4162, USA
J Alzheimers Dis 5:375-82. 2003..Our finding supports the clinical belief of the existence of a change point during cognitive decline among AD patients and suggests the use of change point models for the longitudinal modeling of cognitive decline in AD research...
- Vitamin E and Alzheimer disease: the basis for additional clinical trialsM Grundman
Alzheimer s Disease Cooperative Study, 9500 Gilman Drive 0949, La Jolla, CA, 92093 0949, USA
Am J Clin Nutr 71:630S-636S. 2000..A new clinical trial is planned that will examine whether vitamin E can delay or prevent a clinical diagnosis of Alzheimer disease in elderly persons with mild cognitive impairment...
- Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman
Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
Arch Neurol 61:59-66. 2004..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
- Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairmentMichael Grundman
Department of Neurosciences, University of California, San Diego, La Jolla 92093 0949, USA
J Mol Neurosci 20:241-8. 2003..We conclude that the relationship between hippocampal volume and risk of AD is likely tied to reduced memory performance and not associated with impairment in nonmemory cognitive domains...
- A phase I study of AIT-082 in healthy elderly volunteersMichael Grundman
Department of Neurosciences, University of California, San Diego, La Jolla 92037, USA
J Mol Neurosci 18:283-93. 2002..In conclusion, AIT-082 was rapidly absorbed by the oral route with a half-life suitable for once daily dosing. No problems with tolerability or safety were demonstrated...
- Antioxidant strategies for Alzheimer's diseaseMichael Grundman
Alzheimer s Disease Cooperative Study, University of California, San Diego, 8950 Villa La Jolla Drive, Suite 2200, La Jolla, California 92037, USA
Proc Nutr Soc 61:191-202. 2002..Nevertheless, the clinical value of these agents for AD prevention and treatment is ambiguous, and will remain so until properly designed human trials have been performed...
- Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trialMichael Grundman
Department of Neurosciences, University of California, San Diego, La Jolla, USA
J Mol Neurosci 19:23-7. 2002..In summary, these data suggest that MRI hippocampal volume may be a useful correlate of disease severity in MCI subjects and a prognostic indicator of subsequent AD...
- A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patientsM Grundman
Department of Neurosciences, University of California San Diego, 9500 Gilman, La Jolla, CA 92093, USA
Life Sci 73:539-53. 2003..No problems with tolerability or safety were found. AIT-082 appears suitable for testing in larger clinical trials for the treatment of AD and other neurologic disorders...
- Donepezil delays progression to AD in MCI subjects with depressive symptomsP H Lu
Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Neurology 72:2115-21. 2009..To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship...
- Report of the task force on designing clinical trials in early (predementia) ADP S Aisen
Department of Neurosciences, UCSD, 9500 Gilman Drive M C 0949, La Jolla, CA 92093, USA
Neurology 76:280-6. 2011..The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia...
- Prevalence of symptoms on the CERAD behavior rating scale for dementia in normal elderly subjects and Alzheimer's disease patientsR E Tractenberg
Department of Neurosciences, University of California, San Diego 92093 0949, USA
J Neuropsychiatry Clin Neurosci 12:472-9. 2000..The authors conclude that assessment of behavior in long-term studies will be needed to quantify "abnormal" levels, and that item-level BRSD information could be important in clinical trials...
- Estrogen levels do not correlate with improvement in cognitionLeon J Thal
Department of Neurosciences, University of California, San Diego, School of Medicine, 9500 Gilman Dr, La Jolla, CA 92093, USA
Arch Neurol 60:209-12. 2003..To investigate whether an association exists between estradiol and estrone levels and measures of cognitive functioning in women with Alzheimer disease (AD) treated with conjugated equine estrogen (Premarin; Wyeth-Ayerst, Philadelphia, Pa)...
- Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairmentAdam Fleisher
Department of Neurosciences, University of California San Diego, La Jolla, Calif, USA
Arch Neurol 62:953-7. 2005..The presence of the apolipoprotein E epsilon4 (APOE*E4) allele has been associated with greater hippocampal atrophy in women than in men with Alzheimer disease. This relationship has not been demonstrated in MCI...
- Is there a rationale for including only patients already being treated with acetylcholinesterase inhibitors in a prodromal AD trial?M Grundman
Global R and D Partners, LLC, San Diego, CA, USA
J Nutr Health Aging 16:336-8. 2012....
- Idebenone treatment fails to slow cognitive decline in Alzheimer's diseaseL J Thal
Department of Neurosciences, University of California San Diego School of Medicine, La Jolla 92093 0624, USA
Neurology 61:1498-502. 2003..To determine the effect of idebenone on the rate of decline in Alzheimer's disease (AD)...
- Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative StudyR A Mulnard
Institute for Brain Aging and Dementia, University of California, Irvine 92697 4540, USA
JAMA 283:1007-15. 2000..Several reports from small clinical trials have suggested that estrogen replacement therapy may be useful for the treatment of Alzheimer disease (AD) in women...
- 2012: A watershed year for Alzheimer's disease researchM Grundman
Global RandD Partners, LLC, San Diego, CA, USA
J Nutr Health Aging 17:51-3. 2013....
- A quarter century of advancing treatment for Alzheimer's disease with Leon J. ThalMichael Grundman
Alzheimer's Disease Clinical Development Program, Elan Pharmaceuticals, Inc, San Francisco, CA, USA
Alzheimers Dement 4:S51-5. 2008
- Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trialPaul S Aisen
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
JAMA 289:2819-26. 2003....
- A neuropsychological test battery for use in Alzheimer disease clinical trialsJohn Harrison
CPC Pharma Services, PO Box 3223, Warminster, Wiltshire BA12 8XA, England
Arch Neurol 64:1323-9. 2007....
- Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCIClifford R Jack
Department of Radiology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Neurobiol Aging 29:1285-95. 2008..000). Results of this study support the feasibility of using MRI as an outcome measure of disease progression in multi center therapeutic trials for MCI...
- Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementiaCharles DeCarli
Department of Neurology and Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis, Sacramento 95817, USA
Arch Neurol 64:108-15. 2007..Prognostic uncertainty suggests the need for additional measures to assist the clinician...
- Vitamin E and donepezil for the treatment of mild cognitive impairmentRonald C Petersen
Mayo Clinic College of Medicine, Rochester, Minn, USA
N Engl J Med 352:2379-88. 2005....
- A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's diseaseClifford Singer
Department of Psychiatry, Oregon Health and Science University, Portland, USA
Sleep 26:893-901. 2003..To determine the safety and efficacy of 2 dose formulations of melatonin for the treatment of insomnia in patients with Alzheimer's disease...
- A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's diseaseDale B Schenk
Elan Pharmaceuticals, San Francisco, CA 94080, USA
Neurodegener Dis 2:255-60. 2005..These findings have led to newer alternative A beta immunotherapy approaches that include both active and passive approaches that are currently in clinical testing in both the USA and Europe...
- Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitisMichael Pride
Wyeth Research, Collegeville, PA 19426, USA
Neurodegener Dis 5:194-6. 2008..In a phase 2a clinical trial of AN1792 (Study 201), a potential immunotherapeutic agent for use in Alzheimer's disease (AD), approximately 6% of the treated AD patients (18/300) developed meningoencephalitis (ME)...
- Laboratory investigations and treatment in frontotemporal dementiaFlorence Pasquier
CHRU Clinique Neurologie, Lille. France
Ann Neurol 54:S32-5. 2003
- NSAIDs and hypertensionPaul S Aisen
Arch Intern Med 163:1115; author reply 1115-6. 2003
- Weight loss in the elderly may be a sign of impending dementiaMichael Grundman
Arch Neurol 62:20-2. 2005